Citizens Financial Group Inc. RI Has $23.30 Million Position in Stryker Corporation $SYK

Citizens Financial Group Inc. RI increased its position in shares of Stryker Corporation (NYSE:SYK) by 1.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 58,886 shares of the medical technology company’s stock after acquiring an additional 966 shares during the period. Citizens Financial Group Inc. RI’s holdings in Stryker were worth $23,297,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in SYK. Consolidated Portfolio Review Corp lifted its stake in Stryker by 4.2% during the second quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company’s stock worth $256,000 after purchasing an additional 26 shares during the last quarter. Princeton Global Asset Management LLC lifted its position in shares of Stryker by 16.9% during the 2nd quarter. Princeton Global Asset Management LLC now owns 180 shares of the medical technology company’s stock worth $71,000 after buying an additional 26 shares during the last quarter. Sunflower Bank N.A. lifted its position in shares of Stryker by 4.0% during the 2nd quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company’s stock worth $275,000 after buying an additional 27 shares during the last quarter. Pitti Group Wealth Management LLC boosted its stake in Stryker by 3.2% in the second quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock valued at $341,000 after buying an additional 27 shares in the last quarter. Finally, Sachetta LLC grew its position in Stryker by 58.7% in the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after acquiring an additional 27 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Trading Down 3.0%

NYSE:SYK opened at $362.39 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The firm’s fifty day moving average is $371.96 and its 200-day moving average is $381.22. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19. The firm has a market cap of $138.59 billion, a P/E ratio of 48.00, a P/E/G ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, topping the consensus estimate of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. During the same period last year, the company posted $2.87 EPS. The business’s quarterly revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities analysts expect that Stryker Corporation will post 13.47 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Barclays increased their target price on shares of Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Wells Fargo & Company upped their price objective on shares of Stryker from $452.00 to $456.00 and gave the stock an “overweight” rating in a research report on Friday. Truist Financial raised their target price on shares of Stryker from $392.00 to $400.00 and gave the company a “hold” rating in a research report on Friday. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $435.00 target price on shares of Stryker in a research note on Friday. Finally, Evercore ISI lowered their price target on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a report on Friday, October 31st. Thirteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $434.37.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 276,173 shares of Stryker stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the sale, the director directly owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. The trade was a 9.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Viju Menon sold 500 shares of the company’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 520,500 shares of company stock valued at $184,803,065 in the last quarter. 5.90% of the stock is currently owned by company insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.